Role of P-glycoprotein in mediating rivastigmine effect on amyloid-β brain load and related pathology in Alzheimer's disease mouse model

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1862, Issue 4, 2016, Pages 778-787

  Mohamed, Loqman A ^a   Keller, Jeffrey N ^b   Kaddoumi, Amal ^a  

^a UNIVERSITY OF LOUISIANA AT MONROE   (United States)

^b PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

Author keywords

Alzheimer's disease; Amyloid beta; Astrogliosis; Neuroprotection; P glycoprotein; Rivastigmine

Indexed keywords

AMYLOID BETA PROTEIN; INTERLEUKIN 1BETA; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; POSTSYNAPTIC DENSITY PROTEIN 95; RIVASTIGMINE; SYNAPTOSOMAL ASSOCIATED PROTEIN 25;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTROCYTE; BRAIN HOMOGENATE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOHISTOCHEMISTRY; KNOCKOUT MOUSE; MOUSE; MOUSE MODEL; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; WESTERN BLOTTING;

EID: 84958246985     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2016.01.013     Document Type: Article

References (54)

1. Selkoe D.J. Toward a comprehensive theory for Alzheimer's disease. Hypothesis: Alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid beta-protein. Ann. N. Y. Acad. Sci. 2000, 924:17-25.
2. Selkoe D.J. The molecular pathology of Alzheimer's disease. Neuron 1991, 6:487-498.
3. Querfurth H.W., LaFerla F.M. Alzheimer's disease. N. Engl. J. Med. 2010, 362:329-344.
4. Geula C., Mesulam M.M. Systematic regional variations in the loss of cortical cholinergic fibers in Alzheimer's disease. Cereb. Cortex 1996, 6:165-177.
5. Perry E., Walker M., Grace J., Perry R. Acetylcholine in mind: a neurotransmitter correlate of consciousness?. Trends Neurosci. 1999, 22:273-280.
6. Babic T. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J. Neurol. Neurosurg. Psychiatry 1999, 67:558.
7. Shen H., Kihara T., Hongo H., Wu X., Kem W.R., Shimohama S., Akaike A., Niidome T., Sugimoto H. Neuroprotection by donepezil against glutamate excitotoxicity involves stimulation of alpha7 nicotinic receptors and internalization of NMDA receptors. Br. J. Pharmacol. 2010, 161:127-139.
8. Kim H.G., Moon M., Choi J.G., Park G., Kim A.J., Hur J., Lee K.T., Oh M.S. Donepezil inhibits the amyloid-beta oligomer-induced microglial activation in vitro and in vivo. Neurotoxicology 2014, 40:23-32.
9. Ballard C.G., Chalmers K.A., Todd C., McKeith I.G., O'Brien J.T., Wilcock G., Love S., Perry E.K. Cholinesterase inhibitors reduce cortical Abeta in dementia with Lewy bodies. Neurology 2007, 68:1726-1729.
10. Bailey J.A., Lahiri D.K. A novel effect of rivastigmine on pre-synaptic proteins and neuronal viability in a neurodegeneration model of fetal rat primary cortical cultures and its implication in Alzheimer's disease. J. Neurochem. 2010, 112:843-853.
11. Bailey J.A., Ray B., Greig N.H., Lahiri D.K. Rivastigmine lowers Abeta and increases sAPPalpha levels, which parallel elevated synaptic markers and metabolic activity in degenerating primary rat neurons. PLoS One 2011, 6.
12. Yang H.-Q., Sun Z.-K., Yang W.-M., Han H.-M., Ma J.-J., Li W. Effects of rivastigmine on secreted amyloid precursor protein and beta-amyloid secretion in neuroblastoma SK-N-SH cells. Neurochem. J. 2013, 7:215-220.
13. Mohamed L.A., Qosa H., Kaddoumi A. Age-related decline in brain and hepatic clearance of amyloid-beta is rectified by the cholinesterase inhibitors donepezil and rivastigmine in rats. ACS Chem. Neurosci. 2015.
14. Rogers S.L., Farlow M.R., Doody R.S., Mohs R., Friedhoff L.T. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil study group. Neurology 1998, 50:136-145.
15. Lahiri D.K., Farlow M.R., Sambamurti K., Greig N.H., Giacobini E., Schneider L.S. A critical analysis of new molecular targets and strategies for drug developments in Alzheimer's disease. Curr. Drug Targets 2003, 4:97-112.
16. Sommer B. Alzheimer's disease and the amyloid cascade hypothesis: ten years on. Curr. Opin. Pharmacol. 2002, 2:87-92.
17. Sagare A.P., Bell R.D., Zlokovic B.V. Neurovascular dysfunction and faulty amyloid beta-peptide clearance in Alzheimer disease. Cold Spring Harb. Perspect. Med. 2012, 2.
18. Mawuenyega K.G., Sigurdson W., Ovod V., Munsell L., Kasten T., Morris J.C., Yarasheski K.E., Bateman R.J. Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science 2010, 330:1774.
19. Hardy J.A., Higgins G.A. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992, 256:184-185.
20. Lee G., Bendayan R. Functional expression and localization of P-glycoprotein in the central nervous system: relevance to the pathogenesis and treatment of neurological disorders. Pharm. Res. 2004, 21:1313-1330.
21. Vogelgesang S., Warzok R.W., Cascorbi I., Kunert-Keil C., Schroeder E., Kroemer H.K., Siegmund W., Walker L.C., Pahnke J. The role of P-glycoprotein in cerebral amyloid angiopathy; implications for the early pathogenesis of Alzheimer's disease. Curr. Alzheimer Res. 2004, 1:121-125.
22. Vogelgesang S., Cascorbi I., Schroeder E., Pahnke J., Kroemer H.K., Siegmund W., Kunert-Keil C., Walker L.C., Warzok R.W. Deposition of Alzheimer's beta-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly non-demented humans. Pharmacogenetics 2002, 12:535-541.
23. Silverberg G.D., Messier A.A., Miller M.C., Machan J.T., Majmudar S.S., Stopa E.G., Donahue J.E., Johanson C.E. Amyloid efflux transporter expression at the blood-brain barrier declines in normal aging. J. Neuropathol. Exp. Neurol. 2010, 69:1034-1043.
24. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., Yang F., Cole G. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 1996, 274:99-102.
25. Cirrito J.R., Deane R., Fagan A.M., Spinner M.L., Parsadanian M., Finn M.B., Jiang H., Prior J.L., Sagare A., Bales K.R., Paul S.M., Zlokovic B.V., Piwnica-Worms D., Holtzman D.M. P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. J. Clin. Invest. 2005, 115:3285-3290.
26. Hsiao K.K., Borchelt D.R., Olson K., Johannsdottir R., Kitt C., Yunis W., Xu S., Eckman C., Younkin S., Price D., et al. Age-related CNS disorder and early death in transgenic FVB/N mice overexpressing Alzheimer amyloid precursor proteins. Neuron 1995, 15:1203-1218.
27. Qosa H., Abuznait A.H., Hill R.A., Kaddoumi A. Enhanced brain amyloid-beta clearance by rifampicin and caffeine as a possible protective mechanism against Alzheimer's disease. J. Alzheimers Dis. 2012, 31:151-165.
28. Jann M.W., Shirley K.L., Small G.W. Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Clin. Pharmacokinet. 2002, 41:719-739.
29. Birks J., Evans J.G., Iakovidou V., Tsolaki M. Rivastigmine for Alzheimer's disease. Cochrane Database Syst. Rev. 2000.
30. Chiu C., Miller M.C., Monahan R., Osgood D.P., Stopa E.G., Silverberg G.D. P-glycoprotein expression and amyloid accumulation in human aging and Alzheimer's disease: preliminary observations. Neurobiol. Aging 2015.
31. Zlokovic B.V. Neurovascular mechanisms of Alzheimer's neurodegeneration. Trends Neurosci. 2005, 28:202-208.
32. Deane R., Wu Z., Sagare A., Davis J., Yan S.D., Hamm K., Xu F., Parisi M., LaRue B., Hu H.W., Spijkers P., Guo H., Song X., Lenting P.J., Van Nostrand W.E., Zlokovic B.V. LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron 2004, 43:333-344.
33. Abuznait A.H., Qosa H., Busnena B.A., El Sayed K.A., Kaddoumi A. Olive-oil-derived oleocanthal enhances beta-amyloid clearance as a potential neuroprotective mechanism against Alzheimer's disease: in vitro and in vivo studies. ACS Chem. Neurosci. 2013, 4:973-982.
34. Lam F.C., Liu R., Lu P., Shapiro A.B., Renoir J.M., Sharom F.J., Reiner P.B. Beta-amyloid efflux mediated by p-glycoprotein. J. Neurochem. 2001, 76:1121-1128.
35. Clifford P.M., Zarrabi S., Siu G., Kinsler K.J., Kosciuk M.C., Venkataraman V., D'Andrea M.R., Dinsmore S., Nagele R.G. Abeta peptides can enter the brain through a defective blood-brain barrier and bind selectively to neurons. Brain Res. 2007, 1142:223-236.
36. Krohn M., Lange C., Hofrichter J., Scheffler K., Stenzel J., Steffen J., Schumacher T., Bruning T., Plath A.S., Alfen F., Schmidt A., Winter F., Rateitschak K., Wree A., Gsponer J., Walker L.C., Pahnke J. Cerebral amyloid-beta proteostasis is regulated by the membrane transport protein ABCC1 in mice. J. Clin. Invest. 2011, 121:3924-3931.
37. Yousif S., Marie-Claire C., Roux F., Scherrmann J.M., Decleves X. Expression of drug transporters at the blood-brain barrier using an optimized isolated rat brain microvessel strategy. Brain Res. 2007, 1134:1-11.
38. Agarwal S., Uchida Y., Mittapalli R.K., Sane R., Terasaki T., Elmquist W.F. Quantitative proteomics of transporter expression in brain capillary endothelial cells isolated from P-glycoprotein (P-gp), breast cancer resistance protein (Bcrp), and P-gp/Bcrp knockout mice. Drug Metab. Dispos. 2012, 40:1164-1169.
39. Vaucher E., Aumont N., Pearson D., Rowe W., Poirier J., Kar S. Amyloid beta peptide levels and its effects on hippocampal acetylcholine release in aged, cognitively-impaired and -unimpaired rats. J. Chem. Neuroanat. 2001, 21:323-329.
40. Kar S., Issa A.M., Seto D., Auld D.S., Collier B., Quirion R. Amyloid beta-peptide inhibits high-affinity choline uptake and acetylcholine release in rat hippocampal slices. J. Neurochem. 1998, 70:2179-2187.
41. Lane R.M., Potkin S.G., Enz A. Targeting acetylcholinesterase and butyrylcholinesterase in dementia. Int. J. Neuropsychopharmacol. 2006, 9:101-124.
42. Inglis F. The tolerability and safety of cholinesterase inhibitors in the treatment of dementia. Int. J. Clin. Pract. Suppl. 2002, 45-63.
43. Zlokovic B.V., Yamada S., Holtzman D., Ghiso J., Frangione B. Clearance of amyloid beta-peptide from brain: transport or metabolism?. Nat. Med. 2000, 6:718-719.
44. Ito S., Ohtsuki S., Terasaki T. Functional characterization of the brain-to-blood efflux clearance of human amyloid-beta peptide (1-40) across the rat blood-brain barrier. Neurosci. Res. 2006, 56:246-252.
45. Mohamed L.A., Kaddoumi A. In vitro investigation of amyloid-beta hepatobiliary disposition in sandwich-cultured primary rat hepatocytes. Drug Metab. Dispos. 2013, 41:1787-1796.
46. Shigeri Y., Seal R.P., Shimamoto K. Molecular pharmacology of glutamate transporters, EAATs and VGLUTs. Brain Res. Brain Res. Rev. 2004, 45:250-265.
47. Danbolt N.C. Glutamate uptake. Prog. Neurobiol. 2001, 65:1-105.
48. Theodossiadis G.P., Grigoropoulos V.G., Liarakos V.S., Rouvas A., Emfietzoglou I., Theodossiadis P.G. Restoration of the photoreceptor layer and improvement of visual acuity in successfully treated optic disc pit maculopathy: a long follow-up study by optical coherence tomography. Graefes Arch. Clin. Exp. Ophthalmol. 2012, 250:971-979.
49. Wyss-Coray T., Mucke L. Inflammation in neurodegenerative disease-a double-edged sword. Neuron 2002, 35:419-432.
50. Selkoe D.J. Translating cell biology into therapeutic advances in Alzheimer's disease. Nature 1999, 399:A23-A31.
51. Cummings J.L., Vinters H.V., Cole G.M., Khachaturian Z.S. Alzheimer's disease: etiologies, pathophysiology, cognitive reserve, and treatment opportunities. Neurology 1998, 51. S2-17; discussion S65-17.
52. Mucke L., Selkoe D.J. Neurotoxicity of amyloid beta-protein: synaptic and network dysfunction. Cold Spring Harb. Perspect. Med. 2012, 2:a006338.
53. Owen J.B., Sultana R., Aluise C.D., Erickson M.A., Price T.O., Bu G., Banks W.A., Butterfield D.A. Oxidative modification to LDL receptor-related protein 1 in hippocampus from subjects with Alzheimer disease: implications for Abeta accumulation in AD brain. Free Radic. Biol. Med. 2010, 49:1798-1803.
54. Sagare A., Deane R., Bell R.D., Johnson B., Hamm K., Pendu R., Marky A., Lenting P.J., Wu Z., Zarcone T., Goate A., Mayo K., Perlmutter D., Coma M., Zhong Z., Zlokovic B.V. Clearance of amyloid-beta by circulating lipoprotein receptors. Nat. Med. 2007, 13:1029-1031.